Search results for "Serostatus"

showing 5 items of 5 documents

PML risk stratification using anti-JCV antibody index and L-selectin

2015

Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters. Objective: This study aimed at verifying and integrating both parameters into one algorithm for risk stratification. Methods: Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patient…

0301 basic medicineOncologymedicine.medical_specialtyMultiple SclerosisvirusesMedizinOpportunistic InfectionsAntibodies ViralBioinformaticsRisk AssessmentImmunocompromised Host03 medical and health sciences0302 clinical medicineNatalizumabRisk FactorsInternal medicineHumansMedicineSerologic TestsL-SelectinRisk factorRetrospective Studiesbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisIncidence (epidemiology)Leukoencephalopathy Progressive Multifocalvirus diseasesmedicine.diseaseJC VirusEuropeTreatment Outcome030104 developmental biologyNeurologyRelative riskBiomarker (medicine)Neurology (clinical)businessSerostatusAlgorithmsBiomarkers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Trans…

2019

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%) were all…

AdultMaleOncologymedicine.medical_specialtyPremedicationmedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationAntiviral AgentsAllogeneic hematopoietic stem cells transplantationMechanistic target of rapamycin inhibitorQuantitative PCR03 medical and health sciences0302 clinical medicineTime-to-event analysisInternal medicineHumansTransplantation HomologousMedicineCumulative incidenceCytomegalovirus diseaseSurvival analysisRetrospective StudiesSirolimusTransplantationDose-Response Relationship Drugbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationPK/PDvirus diseasesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseCytomegalovirus infectionsurgical procedures operativeCytomegalovirus DNAemia030220 oncology & carcinogenesisSirolimusCytomegalovirus InfectionsPreemptive antiviral therapySirolimus exposureFemalebusinessSerostatusImmunosuppressive Agents030215 immunologymedicine.drug
researchProduct

Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation

2018

Sirolimus appears to protect against cytomegalovirus (CMV) in organ transplant recipients. The effect of this drug in allogeneic hematopoietic stem cell transplantation recipients remains unexplored. By means of multivariate continuous-time Markov model analyses, we identified 3 independent covariates that significantly impacted the risk of CMV DNAemia: recipient/donor CMV serostatus, tacrolimus exposure, and sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had a significantly higher probability of having detectable CMV DNAemia. Increasing the tacrolimus trough concentration from 0 to 16 ng/mL increased the probability of patients having detectable CMV DNAemia by…

Malebasic (laboratory) research/science0301 basic medicinemedicine.medical_treatmentCytomegalovirusHematopoietic stem cell transplantationGastroenterologyOrgan transplantation0302 clinical medicineRisk FactorsImmunology and AllergyPharmacology (medical)Whole bloodIncidenceHematopoietic Stem Cell Transplantationvirus diseasesMiddle AgedPrognosissurgical procedures operativeCytomegalovirus Infectionscytomegalovirus (CMV) [infection and infectious agents-viral]Femaleantiviral [antibiotic]pharmacokinetics/pharmacodynamicsImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtyinfectious diseasesirolimus [immunosuppressant-mechanistic target of rapamycin]clinical research/practicetacrolimus [immunosuppressant-calcineurin inhibitor]03 medical and health sciencesInternal medicinemedicineHumansTransplantation HomologousTrough ConcentrationViremiabone marrow/hematopoietic stem cell transplantationAgedSirolimusTransplantationbusiness.industryTransplant RecipientsTacrolimus030104 developmental biologySpainRelative riskSirolimusDNA ViralpharmacologybusinessSerostatusFollow-Up Studies030215 immunology
researchProduct

Effect of cytomegalovirus (CMV) serostatus on the incidence and virological features of active CMV infection in allogeneic stem cell transplant recip…

2011

Microbiology (medical)Malebusiness.industryIncidence (epidemiology)Congenital cytomegalovirus infectionCytomegalovirusmedicine.diseaseVirologySeverity of Illness IndexTissue DonorsInfectious DiseasesCytomegalovirus InfectionsmedicineHumansFemaleVirus ActivationStem cellSerostatusbusinessStem Cell TransplantationClinical infectious diseases : an official publication of the Infectious Diseases Society of America
researchProduct

Seroepidemiology of hepatitis A and B and vaccination status in staff at German schools for the handicapped

2016

This study aims to assess serostatus and vaccination status of hepatitis A and B among staff at schools for the handicapped. We also wanted to investigate factors associated with serostatus, number of infections with hepatitis A/hepatitis B at work, and factors influencing being vaccinated or not. The cross-sectional study was carried out between August 2010 and August 2012 at 13 German schools for severely handicapped. Data were analyzed using blood samples, vaccination documents, and questionnaires. A total of 395 persons participated in our study (response: 59.7%), information on 367 could be used for analysis. Two respondents have been infected with HAV at work, 53.4% were anti-HAV sero…

business.industryCross-sectional studyHepatitis A vaccineHepatitis AHepatitis Bmedicine.disease030210 environmental & occupational healthVirologyVaccination03 medical and health sciences0302 clinical medicineInfectious DiseasesVirologyMarital statusMedicine030212 general & internal medicineYoung adultbusinessSerostatusJournal of Medical Virology
researchProduct